The product is 16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester, a multi-arm bioreducible ionizable lipid constructed around a linear triamino backbone that is decorated with three identical octyldithioethyl-esterified propionate arms and a central N-methyl group. The molecule’s three symmetrically placed disulfide bonds serve as independent redox cleavage sites, while the 8-methyl substitution modulates the tertiary amine pKa and steric environment. This extended, branched architecture allows the lipid to form exceptionally stable lipid nanoparticles with high nucleic acid loading capacity, making 16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester a powerful tool for multivalent delivery applications where controlled, glutathione-triggered disassembly is paramount.
16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester is a next-generation ionizable lipid that expands the concept of stimulus-responsive carriers by incorporating three disulfide-linked C8 tails onto a single, extended triamino scaffold. In LNP formulations, this multidentate hydrophobicity anchors the lipid firmly within the nanoparticle core during storage and circulation, yet the relatively short octyl chains ensure that upon intracellular reduction, the liberated thiol fragments are small enough for rapid renal elimination. The central triamino motif of 16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester provides three ionizable nitrogen atoms whose protonation states shift as the endosome matures from early to late stages, creating a sustained membrane-destabilizing effect that boosts the cytoplasmic delivery of messenger RNA and other nucleic acid payloads. Because all three hydrophobic arms are connected through oxidizable disulfide bonds, 16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester degrades predictably and completely in the reductive cytosol, leaving no residual amphiphilic metabolites that could interfere with subsequent doses. This lipid has attracted particular interest in the development of repeat-dose gene therapies for metabolic liver diseases and in the design of self-amplifying RNA vaccines where durable, high-level transgene expression is required from a single injection.
GMP-certified campus spanning 100+ mu, 3 multi-purpose workshops, 6 D-grade clean zone production lines, and 150+ reactors (20L–5000L), supporting high/low temp, anaerobic & hydrogenation; kg to ton scale production.
Fast Delivery
R&D samples: one week; commercial orders: 1–2 months after payment. Express (DHL/FedEx) or air/sea freight available.
Global Partners
Trusted by 30+ pharmaceutical companies in USA, Europe, India, Brazil, and Southeast Asia; long-term cooperation with generic drug manufacturers, CROs, and impurity standard distributors.
Licensed Exporter
Valid drug import/export license — no compliance delays.
Dual Quality Grades
Both research/pharma grade(≥98%)and high-purity impurity grade(≥99%)available to meet diverse customer needs.
Quality Assurance at Cosperpharm
Each batch undergoes:
● Gas chromatography (GC) – purity ≥97.0%
● Non‑aqueous titration – purity ≥97.0%
● Refractive index – confirmatory analysis
● ¹H NMR – structural verification
● Appearance – colorless to light yellow to light orange clear liquid
A comprehensive COA, MSDS (with full GHS information), and certificate of origin accompany every shipment.
Application Scenarios
1.Self-Amplifying RNA Vaccine Formulation
16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester encapsulates large replicon RNAs for potent, single-dose vaccine candidates with extended antigen expression.
2.Liver-Directed Metabolic Gene Therapy
The lipid enables repeat intravenous dosing of mRNA encoding deficient metabolic enzymes, with tri-disulfide clearance preventing cumulative hepatic lipidosis.
3.Oncology mRNA Therapeutics
Used to deliver cytokine or bispecific T-cell engager mRNA to the liver or tumor microenvironment, leveraging glutathione-triggered release for tumor-selective protein expression.
4.Multi-cistronic CRISPR Delivery
Co-formulates base editor or prime editor mRNA with guide RNA and donor templates on a single LNP, with the lipid’s high capacity accommodating long transcripts.
5.Redox-Responsive Library Screening
Serves as a multi-disulfide template in combinatorial studies that vary arm number, chain length, and disulfide placement to derive structure-activity relationships.
6.GLP Toxicology Studies
Cosperpharm supplies characterized 16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester with full analytical support for IND-enabling toxicology, pharmacokinetics, and biodistribution studies.
Contact us
When your delivery challenge demands a bioreducible lipid that is stable enough for manufacturing yet labile enough for cytosolic release, 16-Oxa-19,20-dithia-4,8,12-triazaoctacosanoic acid, 8-methyl-4,12-bis[3-[2-(octyldithio)ethoxy]-3-oxopropyl]-15-oxo-, 2-(octyldithio)ethyl ester is the answer. Let Cosperpharm be your supply partner — contact us to request a sample, discuss scale-up timelines, or schedule a technical review of our analytical data package.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies.Privacy Policy